Julius Knowles - Net Worth and Insider Trading

Julius Knowles Net Worth

The estimated net worth of Julius Knowles is at least $33 Million dollars as of 2024-05-19. Julius Knowles is the Director of Keros Therapeutics Inc and owns about 621,952 shares of Keros Therapeutics Inc (KROS) stock worth over $33 Million. Details can be seen in Julius Knowles's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Julius Knowles has not made any transactions after 2021-12-02 and currently still holds the listed stock(s).

Transaction Summary of Julius Knowles

To

Julius Knowles Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Julius Knowles owns 1 companies in total, including Keros Therapeutics Inc (KROS) .

Click here to see the complete history of Julius Knowles’s form 4 insider trades.

Insider Ownership Summary of Julius Knowles

Ticker Comapny Transaction Date Type of Owner
KROS Keros Therapeutics Inc 2021-12-02 director

Julius Knowles Latest Holdings Summary

Julius Knowles currently owns a total of 1 stock. Julius Knowles owns 621,952 shares of Keros Therapeutics Inc (KROS) as of December 2, 2021, with a value of $33 Million.

Latest Holdings of Julius Knowles

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KROS Keros Therapeutics Inc 2021-12-02 621,952 52.28 32,515,651

Holding Weightings of Julius Knowles


Julius Knowles Form 4 Trading Tracker

According to the SEC Form 4 filings, Julius Knowles has made a total of 15 transactions in Keros Therapeutics Inc (KROS) over the past 5 years, including 1 buys and 14 sells. The most-recent trade in Keros Therapeutics Inc is the sale of 47,651 shares on December 2, 2021, which brought Julius Knowles around $3 Million.

Insider Trading History of Julius Knowles

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Julius Knowles Trading Performance

GuruFocus tracks the stock performance after each of Julius Knowles's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Julius Knowles is 32.59%. GuruFocus also compares Julius Knowles's trading performance to market benchmark return within the same time period. The performance of stocks bought by Julius Knowles within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Julius Knowles's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Julius Knowles

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 23.76
Relative Return to S&P 500(%) 21.65

Julius Knowles Ownership Network

Ownership Network List of Julius Knowles

No Data

Ownership Network Relation of Julius Knowles


Julius Knowles Owned Company Details

What does Keros Therapeutics Inc do?

Who are the key executives at Keros Therapeutics Inc?

Julius Knowles is the director of Keros Therapeutics Inc. Other key executives at Keros Therapeutics Inc include Chief Financial Officer Keith Regnante , Chief Scientific Officer Jennifer Lachey , and Chief Operating Officer Christopher Rovaldi .

Keros Therapeutics Inc (KROS) Insider Trades Summary

Over the past 18 months, Julius Knowles made no insider transaction in Keros Therapeutics Inc (KROS). Other recent insider transactions involving Keros Therapeutics Inc (KROS) include a net sale of 80,000 shares made by Keith Regnante ,

In summary, during the past 3 months, insiders sold 0 shares of Keros Therapeutics Inc (KROS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 80,000 shares of Keros Therapeutics Inc (KROS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 80,000 shares.

Keros Therapeutics Inc (KROS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Keros Therapeutics Inc Insider Transactions

No Available Data

Julius Knowles Mailing Address

Above is the net worth, insider trading, and ownership report for Julius Knowles. You might contact Julius Knowles via mailing address: C/o Keros Therapeutics, Inc., 99 Hayden Avenue, Suite 120, Building E, Lexington Ma 02421.

Discussions on Julius Knowles

No discussions yet.